Smoking history is associated to cognitive impairment in Parkinson's disease

Abstract

Introduction: Patients with Parkinson's disease (PD) are more likely to suffer from cognitive impairment and dementia than healthy older adults. The aim of this study was to investigate smoking history as a risk factor for cognitive decline in PD.

Method: One hundred thirty-nine PD patients aged 50 years and older (Hoehn and Yahr = 1–3) were recruited from a clinical database. Global cognitive function was assessed with the Mini-Mental State Examination (MMSE) and smoking history was investigated as part of a standard clinical interview. A multiple linear regression analysis was used to develop a model for predicting participants' MMSE scores from age, education, Hoehn and Yahr stage, disease duration, the number of vascular risk factors and the number of smoking pack-years.

Results: The regression model significantly accounted for 22.9% of the variance in MMSE scores. Significant predictors were education (β = .312, p < .001), age (β = −.215, p = .013) and total smoking pack-years (β = −.180, p = .029). In former smokers, the number of years since quitting had no effect on global cognition and there were no significant difference between patients who had quit smoking more than 10 years ago and those who had quit less than 10 years ago, F(1, 63) = 1.72, p = .195.

Conclusion: Smoking history was associated to global cognitive impairment in PD even in patients who had quit smoking. These results are in line with findings in healthy older adults that have linked smoking to cognitive impairment, global brain atrophy and functional changes. Future studies should consider a broader assessment of cognitive functions.

Keywords:

• mild cognitive impairment
• aging
• vascular risk factors
• cigarette
• tobacco

Acknowledgements

Access to the data for this research has been made possible through the Réseau Parkinson du Québec, Canada.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

Maxime Doiron is supported by a doctoral training award from Parkinson Society Canada and the Canadian Institutes of Health Research – Institute of Neurosciences, Mental Health and Addiction [grant number 201210].